Publications by authors named "Bryan F Burkey"

Claim this Profile
M
MetAP2 inhibition reduces food intake and body weight in a ciliopathy mouse model of obesity.
Tana S Pottorf, Micaella P Fagan, Bryan F Burkey, David J Cho, James E Vath

JCI Insight· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061.
Bryan F Burkey, Niel C Hoglen, Philip Inskeep, Margaret Wyman, Thomas E Hughes

J Pharmacol Exp Ther· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study.
Mi-Jeong Lee, Da-Wei Gong, Bryan F Burkey, Susan K Fried

Am J Physiol Endocrinol Metab· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats.
Alokesh Duttaroy, Frank Voelker, Kimberley Merriam, Xia Zhang, Xianglin Ren, Bryan F Burkey

Eur J Pharmacol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Edwin B Villhauer, John A Brinkman, Goli B Naderi, Bryan F Burkey, Beth E Dunning

J Med Chem· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis